Geode Capital Management, LLC Dbv Technologies S.A. Transaction History

Geode Capital Management, LLC

17 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 13, 2024	BUY	$0.7 - $1.33 $10,579 - $20,100	15,113 Added 63.86%	38,779 $36,000
Q3 2021 Nov 12, 2021	BUY	$4.71 - $5.92 $9,923 - $12,473	2,107 Added 9.77%	23,666 $115,000
Q2 2021 Aug 13, 2021	BUY	$5.32 - $6.53 $22,179 - $27,223	4,169 Added 23.97%	21,559 $117,000
Q1 2021 May 12, 2021	BUY	$2.75 - $6.57 $47,822 - $114,252	17,390 New	17,390 $92,000
Q4 2020 Feb 12, 2021	SELL	$1.38 - $3.01 $42,429 - $92,545	-30,746 Closed	0 $0
Q2 2020 Aug 13, 2020	BUY	$3.74 - $6.28 $45,426 - $76,276	12,146 Added 65.3%	30,746 $134,000
Q1 2020 May 14, 2020	SELL	$2.33 - $12.98 $24,225 - $134,953	-10,397 Reduced 35.86%	18,600 $72,000
Q4 2019 Feb 13, 2020	BUY	$6.75 - $11.15 $70,179 - $115,926	10,397 Added 55.9%	28,997 $310,000
Q2 2019 Aug 14, 2019	SELL	$7.58 - $10.0 $44,115 - $58,200	-5,820 Reduced 23.83%	18,600 $152,000
Q1 2019 May 14, 2019	BUY	$5.81 - $9.37 $1,394 - $2,248	240 Added 0.99%	24,420 $188,000
Q4 2018 Feb 13, 2019	SELL	$5.75 - $21.85 $25,972 - $98,696	-4,517 Reduced 15.74%	24,180 $155,000
Q3 2018 Nov 13, 2018	BUY	$16.81 - $24.58 $5,547 - $8,111	330 Added 1.16%	28,697 $644,000
Q2 2018 Aug 14, 2018	BUY	$18.6 - $24.94 $130,367 - $174,804	7,009 Added 32.82%	28,367 $547,000
Q1 2018 May 15, 2018	BUY	$20.86 - $26.6 $10,951 - $13,965	525 Added 2.52%	21,358 $492,000
Q4 2017 Feb 13, 2018	BUY	$20.9 - $49.36 $73,129 - $172,710	3,499 Added 20.19%	20,833 $512,000
Q3 2017 Nov 14, 2017	SELL	$39.62 - $46.17 $49,564 - $57,758	-1,251 Reduced 6.73%	17,334 $735,000
Q2 2017 Aug 14, 2017	BUY	N/A	18,585	18,585 $663,000

3.2K

Ticker DBVT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 187,776,992
Market Cap $95.8M
Description
DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its lead product candidate is Viaskin Peanut, an immunotherapy product, which has completed Phase III clinical trial for the treatment of peanut allergies in 4 to 11 years of age children, adolescents...

Get notified when there are updates to the investment portfolio of Geode Capital Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Geode Capital Management, LLC with notifications on news.